FDA Salt-Form Restriction: Only Base Semaglutide Can Be Compounded (2026)

What the salt-form issue is

Active pharmaceutical ingredients can exist as a base or as a salt (for example, an acetate or sodium salt). Wegovy and Ozempic use semaglutide base. Some compounders sourced cheaper salt forms, which the FDA considers different, unapproved active ingredients rather than the studied molecule. That distinction is the basis for the agency’s enforcement.

Base vs salt at a glance

How enforcement built

What patients should verify

This is one of the most concrete checks a patient can make. Ask your provider or pharmacy to confirm, in writing, that the active ingredient is semaglutide base, not a salt form. A compliant operator will answer plainly and may provide a certificate of analysis. Evasion, or marketing that implies FDA approval, is a reason to look elsewhere.

Why it matters for safety

Beyond the legal question, salt forms were not the ingredient studied in the trials that established semaglutide’s safety and efficacy. Using a different active ingredient means the clinical evidence does not necessarily transfer, and quality can vary between sources. The base-form requirement is therefore both a compliance rule and a quality signal.

Where this fits

The salt-form restriction is one strand of a broader 2026 tightening that also includes the proposed 503B bulks-list exclusion and misbranding actions. Together they push the market toward documented, base-form, patient-specific compounding and FDA-approved products. See our April 2026 FDA action explainer and provider-selection guide.

How we got here

The salt-form question predates the 2026 tightening. As compounded semaglutide scaled during the shortage, some suppliers turned to lower-cost salt forms, and the FDA responded with early warning letters emphasizing that only base semaglutide is acceptable. What changed in 2025-2026 is enforcement intensity: with the shortage resolved, the agency folded the salt-form issue into a broader campaign against mass-marketed compounded GLP-1s, alongside misbranding actions and the proposed 503B bulks-list exclusion. For patients, the takeaway is durable regardless of how the rules evolve: the base peptide is the studied, defensible ingredient, and a provider that cannot confirm base-form sourcing in plain language is not meeting the standard the agency now expects.

Frequently asked questions

Are salt forms of semaglutide legal to compound?

The FDA treats semaglutide sodium and acetate as unapproved active ingredients. Only the base peptide form is acceptable, and warning letters have cited salt-form use.

How do I know which form my provider uses?

Ask the provider or pharmacy to confirm in writing that the active ingredient is semaglutide base, not a salt form; a compliant operator will answer and may share a certificate of analysis.

Why does the form matter?

Salt forms were not the ingredient studied in semaglutide's trials, so the safety and efficacy evidence may not transfer, and it is an FDA compliance issue.

Is “compounded Wegovy” a valid term?

No. Marketing that calls compounded products “compounded Wegovy” or “FDA-approved” is treated as misbranding; compounded semaglutide is not FDA-approved.